Abstract
Background Genetic polymorphisms have been associated with risk of anti-tuberculosis treatment toxicity. We characterized associations with adverse events and treatment failure/recurrence among adults treated for tuberculosis in Brazil.
Methods Participants were followed in Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil. We included persons with culture-confirmed drug-susceptible pulmonary tuberculosis who started treatment between 2015-2019, and who were evaluable for pharmacogenetics. Treatment included 2 months of isoniazid, rifampin or rifabutin, pyrazinamide, and ethambutol, then 4 months of isoniazid and rifampin or rifabutin, with 24 month follow-up. Analyses included 43 polymorphisms in 20 genes related to anti-tuberculosis drug hepatotoxicity or pharmacokinetics. Whole exome sequencing was done in a case-control toxicity subset.
Results Among 903 participants in multivariable genetic association analyses, NAT2 slow acetylator status was associated with increased risk of treatment-related grade 2 or greater adverse events, including hepatotoxicity. Treatment failure/recurrence was more likely among NAT2 rapid acetylators, but not statistically significant at the 5% level. A GSTM1 polymorphism (rs412543) was associated with increased risk of treatment-related adverse events, including hepatotoxicity. SLCO1B1 polymorphisms were associated with increased risk of treatment- related hepatoxicity and treatment failure/recurrence. Polymorphisms in NR1/2 were associated with decreased risk of adverse events and increased risk of failure/recurrence. In whole exome sequencing, hepatotoxicity was associated with a polymorphism in VTI1A, and the genes METTL17 and PRSS57, but none achieved genome-wide significance.
Conclusions In a clinical cohort representing three regions of Brazil, NAT2 acetylator status was associated with risk for treatment-related adverse events. Additional significant polymorphisms merit investigation in larger study populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Departamento de Ciência e Tecnologia, Secretaria de Ciência e Tecnologia, Ministério da Saúde, Brazil (25029.000507/2013-07); National Institute of Allergy and Infectious Diseases (NIAID) (U01 AI069923, R01 AI120790, U01 AI172064, R01 AI077505, P30 AI110527) and the National Center for Advancing Translational Science (UL1 TR000445) at the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All clinical investigations were conducted according to the principles of the Declaration of Helsinki. The RePORT-Brazil protocol, informed consent, and study documents were approved by the institutional review boards at each study site and at Vanderbilt University Medical Center. Participation in RePORT-Brazil was voluntary, and written informed consent was obtained from all such participants. 1) Vanderbilt University Medical Center: a. Name of Ethics Committee: Human Research Protections Program; Health Sciences Committee 3 IRB 2) Instituto Nacional de Infectologia, FIOCRUZ: a. Name of Ethics Committee: Instituto Nacional de Infectologia Evandro Chagas; INI /FIOCRUZ IRB 3) Centro Municipal de Saúde (CMS) de Duque de Caxias: a. Name of Ethics Committee: Universidade do Grande Rio Professor José de Souza Herdy; UNIGRANRIO IRB 4) Instituto Brasileiro para Investigação da Tuberculose (IBIT): a. Name of Ethics Committee: Maternidade Climério de Oliveira; UFBA IRB 5) Fundação de Medicina Tropical (FMT): a. Name of Ethics Committee: Fundação de Medicina Tropical; Doutor Heitor Vieira Dourado, IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵17 Valeria C. Rolla, Maria Cristina S. Lourenço, Aline Benjamin, Quezia Medeiros de Oliveira, Felipe Ridolfi, Adriano Gomes da Silva, and Marcus Rockembach at Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil; Solange Cavalcante, Betina Durovni, Jamile Garcia, Martinelle Godinho, and João Marine at Secretaria Municipal de Saúde do Rio de Janeiro e Clínica da Família Rinaldo Delamare, Rocinha, Rio de Janeiro, Brazil; Afranio Kritski, Adriana Moreira, André Luiz Bezerra, Anna Cristina Carvalho, and Elisangela Silva at Centro Municipal de Saúde de Duque de Caxias and Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Marcelo Cordeiro dos Santos, Alexandra Brito, Leandro Garcia, Renata Cordeiro dos Santos, Allyson Souza, and Jaquelane Silva at Fundação de Medicina Tropical, Manaus, Brazil; Bruno de Bezerril Andrade, Eduardo M. Netto, Michael Rocha, Vanessa Nascimento, Betânia Nogueira, Saulo R. N. Santos, and André Ramos at Instituto Brasileiro para Investigação da Tuberculose, Fundação José Silveira, Salvador, Brazil; Alice Andrade, Hayna Malta, Juan Cubillos, and Laise de Moraes at Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil; Bruno de Bezerril Andrade, Artur Trancoso, Kiyosh Fukutani, Mariana Araujo Pereira, Maria Arriaga, and Elze Leite at Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Funding: This work was supported by the Departamento de Ciência e Tecnologia–Secretaria de Ciência e Tecnologia–Ministério da Saúde, Brazil (25029.000507/2013-07); National Institute of Allergy and Infectious Diseases (NIAID) (U01 AI069923, R01 AI120790, U01 AI172064, R01 AI077505, P30 AI110527) and the National Center for Advancing Translational Science (UL1 TR000445) at the National Institutes of Health.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
